Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review
2010
Colorectal cancer statistics, 2014
2014 Standout
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer
1997
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
1998 Standout
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome
2010
Testicular cancer and Hodgkin's disease: evaluation of semen quality
2003
Multidrug Resistance in Breast Cancer: a Meta-analysis of MDR1/gp170 Expression and Its Possible Functional Significance
1997
Molecular imaging in drug development
2008 Standout
Cancer-Related Fatigue
2010
Myeloid-derived suppressor cells coming of age
2018 Standout
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes
1997
Fertility preservation for young patients with cancer: who is at risk and what can be offered?
2005
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
2010
The emerging role of reactive oxygen species in cancer therapy
2004
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Oxidative stress, inflammation, and cancer: How are they linked?
2010 Standout
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias
1995
Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study
2008
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
2004 Standout
Sperm aneuploidy frequencies analysed before and after chemotherapy in testicular cancer and Hodgkin's lymphoma patients
2007
The mini-driver model of polygenic cancer evolution
2015 StandoutNobel
Male infertility in long-term survivors of pediatric cancer: a report from the childhood cancer survivor study
2014
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
Colorectal cancer
2013 Standout
Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas
1998
Antibody therapy of cancer
2012 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Targeting multidrug resistance in cancer
2006 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Circos: An information aesthetic for comparative genomics
2009 Standout
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Cancer treatment and survivorship statistics, 2012
2012 Standout
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma
2007
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
2009 StandoutNobel
Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma
2007
Tobacco Smoke Carcinogens and Lung Cancer
1999 Standout
Smoking-related increase of O6-methylguanine-DNA methyltransferase expression in human lung carcinomas
1998
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)
2004
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia:
2004
Late Effects of Hodgkin’s Disease and Its Treatment
2009
Fatigue and Sleep Disturbance in Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study (CCSS)
2008
Cancer as an evolutionary and ecological process
2006 Standout
Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers
2008
Conventional second‐line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first‐line salvage therapy regimens
2005
Mitoxantrone
1996
Preservation of Fertility in Patients with Cancer
2009 Standout
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
2005
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
2009
Secondary Amenorrhea After Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin’s Lymphoma Study Group
2005
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma
2014
IDA‐FLAG (idarubicin, fludarabine, cytarabine, G‐CSF), an effective remission‐induction therapy for poor‐prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial
1998
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
2006
Revised Response Criteria for Malignant Lymphoma
2007 Standout
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
2007 Standout
Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study.
2006
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Reactive species in non-equilibrium atmospheric-pressure plasmas: Generation, transport, and biological effects
2016 Standout
Cancer treatment and survivorship statistics, 2016
2016 Standout
Cancer treatment and survivorship statistics, 2019
2019 Standout
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review
2007
Evolutionary games on graphs
2007 Standout
ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi
2005
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial
2002
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
2006
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
State-of-the-Art Therapeutics: Hodgkin's Lymphoma
2005
In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia
1997
Evolution of cooperation among tumor cells
2006
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy
2014
Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
2007
Hodgkin's lymphoma
2003
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma
2008
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
2006 StandoutScience
Works of B. Lathan being referenced
BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease
1997
Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
1994
Pretherapeutic Drug Testing in Acute Leukemias for Prediction of Individual Prognosis
1990
Cytotoxic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC 312887) in a human tumor cloning system
1988
Male gonadal dysfunction in patients with Hodgkin’s disease prior to treatment
2001
Fatigue in long-term survivors of Hodgkin‘s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG)
2003
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease
2003
High-Dose Versus Intermediate Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age Adjusted Randomized Comparison
1993
Immunohistochemical Detection of P-Glycoprotein in Normal and Malignant Tissues: A Comparative Study of Three Monoclonal Antibodies, JSB-1, C 219 and 265/F4, against Different Epitopes Using Frozen and Paraffin Tissue Sections
1993
Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4.
1988
Improved plating efficiencies for human tumors cloned in capillary tubes versus Petri dishes.
1986
High-Dose Versus Intermediate-Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age-Adjusted Randomized Comparison
1992
Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML.
1992